Management of Pleural Effusion

Diagnosis and Evaluation

• The European Respiratory Society recommends determining if the pleural effusion is transudative or exudative, with transudative effusions often not requiring sampling if the clinical picture is clear, and exudative effusions requiring thorough investigation to determine etiology 1
• Assess for symptoms such as dyspnea, chest pain, cough, and tachypnea, and classify as "clinically significant" if causing respiratory symptoms, with dyspnea often out of proportion to effusion size in pulmonary embolism 2, 1
• Essential tests for pleural fluid include biochemistry, cell count with differential, microbiology, and cytology, with blood cultures obtained in all patients with suspected parapneumonic effusion to guide antibiotic therapy, as recommended by the American Thoracic Society and the British Thoracic Society 3, 4

Follow-up and Monitoring

• Observation is appropriate if the patient is asymptomatic, with follow-up imaging (chest X-ray) scheduled at 4-6 weeks to assess stability 5
• A structured follow-up schedule is recommended, with the first follow-up within 7-10 days after initial assessment, telephone contact between visits for symptom monitoring, and provision of a 24-hour emergency contact number for concerning symptoms 6

Intervention and Treatment

• Intervention is indicated for symptomatic effusions regardless of size, asymptomatic effusions >400 mL, and effusions occupying >25-33% of hemithorax on chest radiograph, with ultrasound-guided thoracentesis preferred over surgical tube thoracostomy 2
• The American Thoracic Society recommends performing initial therapeutic thoracentesis in virtually all dyspneic patients to assess effect on symptoms, and removing 1-1.5L of fluid at one sitting to avoid re-expansion pulmonary edema 7
• Initial therapeutic thoracentesis should be performed with monitoring for complications, such as chest pain, dyspnea, and severe cough, and ideally, pleural fluid pressure should be monitored during the procedure 7
• Enhanced recovery can be achieved with dedicated follow-up and drainage protocols, resulting in up to 15% improvement, and consideration of anti-inflammatory medications for post-pericardiotomy syndrome 2

Recurrent Effusions

• For recurrent effusions, seek advice from a thoracic malignancy multidisciplinary team, consider definitive procedures like pleurodesis for malignant effusions, and note that recurrence rate after aspiration alone approaches 100% at 1 month 5
• Recognize that 21% of effusions may recur despite intervention, and be cautious with bilateral effusions, which may not need sampling if clearly transudative 2, 1
• The American Thoracic Society recommends safe removal of 1-1.5L of fluid at one sitting, unless the patient develops symptoms, and larger volumes may be safe with contralateral mediastinal shift 7
• Malignant pleural effusions are a common complication in patients with cancer, causing significant morbidity and mortality, with various management options available, including PleurX catheter placement, talc pleurodesis, and therapeutic thoracentesis, as recommended by the American Thoracic Society and the British Thoracic Society 5, 5

Management Options

• The choice of management option depends on the underlying cause of the pleural effusion, patient performance status, and symptoms, with a focus on palliative care and symptom management, as emphasized by the National Comprehensive Cancer Network and the European Society of Cardiology 8, 2
• PleurX catheter placement allows for outpatient management of recurrent pleural effusions and results in significantly shorter hospitalization compared to talc pleurodesis (1 day vs 6 days), with a high success rate and minimal complications, as noted by the British Thoracic Society and the European Respiratory Society 5, 2
• PleurX catheter placement can achieve spontaneous pleurodesis in approximately 42-46% of cases, with a significant reduction in recurrence rates and improvement in symptoms, as recommended by the American Thoracic Society and the National Comprehensive Cancer Network 5, 7
• The efficacy of PleurX catheter placement is comparable to talc pleurodesis, with similar symptom control and side effect profiles, as noted by the British Thoracic Society and the European Respiratory Society 9, 2
• Local cellulitis is the most common complication of PleurX catheter placement, occurring in up to 10% of cases, with infection/empyema and tumor seeding along the catheter tract being rare but potentially serious complications, as noted by the British Thoracic Society and the European Respiratory Society 5, 2
• The overall complication rate for PleurX catheter placement is relatively low, ranging from 14-17%, with most complications being minor and manageable, as recommended by the American Thoracic Society and the National Comprehensive Cancer Network 10, 5

Palliative Care

• Early introduction of expert palliative care is recommended for symptom management, including effective management of dyspnea with appropriate interventions, and consideration of pain management, particularly in mesothelioma, as emphasized by the National Comprehensive Cancer Network 8, 7
• Palliative care should be individualized to the patient's needs and preferences, with a focus on improving quality of life and reducing symptoms, as recommended by the American Thoracic Society and the British Thoracic Society 5, 5